Alzheimer’s Drugs Market Share, Growth, & Report by 2030

[Research Report] The Alzheimer’s drugs market is projected to grow from US$ 6.21 billion in 2022 to US$ 22.01 billion by 2030; it is estimated to record a CAGR of 17.1% during 2022–2030.

Market Insights and Analyst View: 

Alzheimer's disease (AD) is a neurological disorder caused by the progressive death of neurons. The symptoms begin gradually and can lead to dementia. Although the condition cannot be cured completely, there are medicines available that can temporarily alleviate the symptoms and slow down the progression of the disease. The high prevalence of AD, particularly in the senior population, and growing research and development activities in the pharmaceutical industry to introduce diagnostics and therapies for the condition are the key factors driving the Alzheimer’s drugs market growth. However, the side effects of drugs and the stringent regulatory environment hinder the market progress. Furthermore, the rising focus on personalized treatments and precision medicines for AD is expected to bring new Alzheimer’s drugs market trends in the coming years.

Growth Drivers and Restraints: 

The growing cases of AD and related dementia propel the Alzheimer’s drugs market size. Alzheimer’s disease is the most common form of dementia worldwide, accounting for 60–70% of all cases. It is a progressive neurodegenerative disease that worsens gradually over the years and is more common in the aging population. As per the World Health Organization (WHO) report published in October 2022, the global population aged 60 years and above will grow to 1.4 billion by 2030 and reach 2.1 billion by 2050. This growing geriatric population is anticipated to increase the disease burden, facilitating the demand for related medical treatments in the coming years.

Furthermore, rising awareness about AD, improving diagnosis rates, and increasing investments in the development of new treatments are the growth enablers of the market. According to a report published by the Alzheimer’s Association in 2021, US$ 63 million was invested by the association in 2020 to advance Alzheimer’s and dementia research.

However, potential side effects express significant implications for the Alzheimer’s drug market progression. Acetylcholinesterase inhibitors (AChEIs) and NMDA receptor antagonists are the class of drugs commonly prescribed for the treatment of AD. Although these drugs are widely used and considered to be generally safe when used as directed, several specific side effects and concerns are associated with their use. The most significant adverse effects associated with AD drugs are dizziness, nausea, diarrhea, and abdominal pain in case of overdosing or when used inappropriately. This is a major concern and can impact consumer confidence in the product, potentially leading to decreased usage. According to an article published in 2021 by ScienceDirect Journal, studies carried out to evaluate adverse reactions of drugs used in the treatment of AD reported cardiac adverse events associated with AChEIs and gastrointestinal side effects such as constipation, diarrhea, vomiting, and abdominal pain associated with Memantine. Thus, the side effects of these drugs hinder the Alzheimer’s drugs market.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Alzheimer's Drugs Market: Strategic Insights

Market Size Value in	US$ 6.21 billion in 2022
Market Size Value by	US$ 22.01 billion by 2030
Growth rate	CAGR of 17.1% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The “Alzheimer’s drugs market analysis” has been carried out by considering the following segments: drug classand distribution channel.

Segmental Analysis:

Based on drug class, the market is segmented into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs. The cholinesterase inhibitors segment accounted for the largest Alzheimer’s drugs market share in 2022. The pipeline drugs segment is estimated to register the highest CAGR during 2022–2030. The cholinesterase inhibitors segment is further segmented into donepezil, galantamine, and rivastigmine. Cholinesterase inhibitors are prescribed by specialists such as psychiatrists or neurologists for early- to mid-stage AD. These drugs boost the levels of acetylcholine in the brain, a neurotransmitter that helps nerve cells communicate with each other.

Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2022, the hospital pharmacies segment held the largest Alzheimer’s drugs market share. The online pharmacies segment is anticipated to register the highest CAGR during 2022–2030. 

Regional Analysis:

The scope of the Alzheimer’s drugs market report entails North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America held the largest share of the global market owing to the extensive research and development activities by pharmaceutical companies, and the prevalence of AD and associated dementia in the aging population in the region. According to the Alzheimer’s Association, in 2023, over 6 million people in America were diagnosed with AD, and ~1 in 9 individuals aged 65 years or above—representing 10.7% of the American population—were affected by Alzheimer’s disease. Additionally, according to statistics provided by the Centers for Disease Control and Prevention (CDC) in October 2020, AD is the sixth leading cause of death among US adults. Furthermore, the increasing spending on healthcare services across the US boosts the demand for AD treatment drugs, favoring the Alzheimer’s drugs market growth in the region.

Alzheimer's Drugs Market Report Scope

Industry Developments and Future Opportunities:

The Alzheimer’s drugs market forecast can help stakeholders in this marketplace plan their growth strategies. A few initiatives taken by key players operating in the global Alzheimer’s drugs market are listed below:

1. In January 2024, Eisai Co., Ltd. and Biogen Inc. announced that the distribution of their collaborative development, LEQEMBI, has been approved in China. It is a humanized, anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody developed for the treatment of mild cognitive impairment (MCI) due to AD and mild AD dementia.
2. In May 2023, Otsuka Pharmaceutical, Co. Ltd. and Lundbeck LLC announced that their collaborative development, supplemental New Drug Application (sNDA) of REXULTI containing brexpiprazole, received the US Food and Drug Administration (FDA) approval for the treatment of neuropsychiatric symptom in Alzheimer’s and dementia.
3. In May 2023, Eli Lilly and Company announced the positive result for TRAILBLAZER-ALZ 2 Phase 3 study of its Alzheimer’s drug, Donanemab. According to the study, Donanemab significantly slowed cognitive and functional decline in people with early symptomatic AD.
4. In September 2022, Corium, Inc. launched ADLARITY, a donepezil transdermal system in the US. It is a prescription drug intended to treat mild, moderate, or severe dementia in patients with AD. This transdermal system is the first and only once-weekly patch that delivers consistent doses of donepezil through the skin and has no gastrointestinal side effects.

Competitive Landscape and Key Companies:

Pfizer Inc.; Siemens Healthcare GmbH; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Sanofi; Novartis AG; AstraZeneca; AbbVie Inc.; Eisai Co., Ltd.; and Takeda Pharmaceutical Company Limited are among the prominent players profiled in the Alzheimer’s drugs market report. In addition, several other players have been studied and analyzed during the study to get a holistic view of the market and its ecosystem.